Table 1.
Participant characteristics
| Characteristic | SMART group (N = 151) | Standard group (N = 152) |
|---|---|---|
| Mean [(standard deviation (SD)] | ||
| Age (years) | 41·3 (13·7) | 42·6 (14·5) |
| ACQ-5 Score | 1·78 (0·99) | 1·79 (2·4) |
| Daily ICS dose (budesonide or equivalent), µg | 805 (353) | 813 (370) |
| On-treatment FEV1 (L) | 2·62 (0·91) | 2·50 (0·78) |
| On-treatment FEV1 % predicted | 81·6 (18·9) | 80·4 (20·5) |
| Severe exacerbations in the prior 12 months | 1·55 (1·31) | 1·73 (1·22) |
| Median (IQR) | ||
| Baseline self-reported reliever usea | 2 (1 to 3) | 2 (1 to 3) |
| Number of hospital admissions ever for asthma | 1 (0 to 4) | 1 (0 to 4) |
| N/151 (%) | N/152 (%) | |
| Male | 48 (31·8) | 46 (30·3) |
| Ethnicity | ||
| European | 113 (74·8) | 118 (77·6) |
| Māori | 25 (16·6) | 19 (12·5) |
| Pacific Islander | 5 (3·3) | 10 (6·6) |
| Other | 8 (5·3) | 5 (3·3) |
| Number of severe exacerbations in previous 12 months | ||
| 0 | 14 (9·3) | 11 (7·2) |
| 1 | 86 (57·0) | 75 (49·3) |
| 2 | 29 (19·2) | 31 (20·4) |
| 3 | 10 (6·6) | 22 (14·5) |
| 4 | 5 (3·3) | 6 (3·9) |
| ≥5 | 7 (4·6) | 7 (4·6) |
| LABA use | 92 (60·9) | 103 (67·8) |
| Combination ICS plus LABA inhaler | 73 (48%) | 82 (54%) |
| Use of written asthma self-management plan | 15 (10%) | 20 (13%) |
| Current smokers | 30 (19·9) | 29 (19·1) |
| Ex-smokers | 49 (32·5) | 48 (31·6) |
| Non-smokers | 72 (47·7) | 75 (49·3) |
ACQ asthma control questionnaire, FEV 1 forced expiratory volume in one second, ICS inhaled corticosteroids, LABA long acting beta-agonist
a As per the ACQ question 6. ACQ question 6 is a categorical score of beta-agonist use over the preceding 7 days in the following bands: score 0—none; score 1—1 to 2 salbutamol inhalations most days; score 2—3 to 4 salbutamol inhalations most days; score 3—5 to 8 salbutamol inhalations most days; score 4—9 to 12 salbutamol inhalations most days; score 5—13 to 16 salbutamol inhalations most days; score 6—more than 16 salbutamol inhalations most days.